Mongolia vs Trinidad and Tobago: Prevalence rate of diabetes in adults
Mongolia
11.7
in 2014
Trinidad and Tobago
11.7
in 2014
Mongolia rank
46th
Trinidad and Tobago rank
46th
Prevalence rate of diabetes in adults over time
- Mongolia
- Trinidad and Tobago
How they compare
Mongolia currently reports 11.7 against 11.7 in Trinidad and Tobago, a difference of 0.
The two have swapped places 1 time across 35 shared years of data; in 1980 it was Mongolia ahead.
Mongolia ranks 46th and Trinidad and Tobago ranks 46th of 190 countries.
Mongolia has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Mongolia | Trinidad and Tobago | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 5.81 | 4.47 | 1.34 | Mongolia |
| 1990s | 7.2 | 5.84 | 1.36 | Mongolia |
| 2000s | 9 | 8.41 | 0.59 | Mongolia |
| 2010s | 11.02 | 10.96 | 0.06 | Mongolia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence rate of diabetes in adults, Mongolia or Trinidad and Tobago?
- Mongolia, at 11.7 against 11.7 in Trinidad and Tobago as of 2014.
- What is the difference in prevalence rate of diabetes in adults between Mongolia and Trinidad and Tobago?
- 0, with Mongolia ahead.
- How many years of comparable data are there for Mongolia and Trinidad and Tobago?
- 35 years are reported by both, from 1980 to 2014.
- How do Mongolia and Trinidad and Tobago rank globally for prevalence rate of diabetes in adults?
- Mongolia ranks 46th and Trinidad and Tobago ranks 46th of 190 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) β with minor processing by Our World in Data, published as Prevalence rate of diabetes in adults. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated share of people with diabetes among those aged over 18, based on general population surveys and statistical modeling. Diabetes is a risk factor for chronic complications, including cardiovascular disease, and premature death.